

Pratiti Nath, Elizabeth Ngoc Hoa Tran, Renato Morona

**Mutational analysis of the *Shigella flexneri* O-antigen polymerase Wzy: Identification of Wzz-dependent Wzy mutants,**

Journal of Bacteriology, 2015; 197(1):108-119

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

**PERMISSIONS**

[http://journals.asm.org/site/misc/ASM\\_Author\\_Statement.xhtml](http://journals.asm.org/site/misc/ASM_Author_Statement.xhtml)

**Authors may post their articles to their institutional repositories**

ASM grants authors the right to post their accepted manuscripts in publicly accessible electronic repositories maintained by funding agencies, as well as appropriate institutional or subject-based open repositories established by a government or non-commercial entity. Since ASM makes the final, typeset articles from its primary-research journals available free of charge on the ASM Journals and PMC websites **6 months after final publication**, ASM recommends that when submitting the accepted manuscript to PMC or institutional repositories, the author specify that the posting release date for the manuscript be no earlier than 6 months after the final publication of the typeset article by ASM.

**23<sup>rd</sup> March 2015**

<http://hdl.handle.net/2440/89367>

1 **Title: Mutational analysis of the *Shigella flexneri* O antigen polymerase Wzy;**  
2 **identification of Wzz-dependent Wzy mutants**

3

4 **Authors:** Pratiti Nath<sup>1</sup>, Elizabeth Ngoc Hoa Tran<sup>1</sup>, and Renato Morona<sup>1#</sup>

5

6 **Address:** <sup>1</sup>Discipline of Microbiology and Immunology, School of Molecular and Biomedical  
7 Science, University of Adelaide, Adelaide, SA 5005, Australia.

8

9 **Running title:** Characterization of *S. flexneri* Wzy.

10

11 **# Corresponding author:** Renato Morona,

12 Email: renato.morona@adelaide.edu.au, Phone: +61 8 8313 4151, Fax: +61 8 8313 7532

13

14

15 **Key Words:** Lipopolysaccharide, O antigen, Wzy, Wzz, Colicin E2, Bacteriophage Sf6,  
16 Mutagenesis, Protein expression.

17

## 18 Abstract

19 The O antigen (Oag) component of lipopolysaccharide (LPS) is a major virulence  
20 determinant of *Shigella flexneri* and is synthesized by the O antigen polymerase, Wzy<sub>Sf</sub>.  
21 Oag chain length is regulated by chromosomally encoded Wzz<sub>Sf</sub> and pHS-2 plasmid  
22 encoded Wzz<sub>pHS2</sub>. To identify functionally important amino acid residues in Wzy<sub>Sf</sub>, random  
23 mutagenesis was performed on the *wzy*<sub>Sf</sub> in a pWaldo-TEV-GFP plasmid followed by  
24 screening with colicin E2. Analysis of the LPS conferred by mutated Wzy<sub>Sf</sub> proteins in the  
25 *wzy*<sub>Sf</sub> deficient ( $\Delta wzy$ ) strain identified 4 different mutant classes, with mutations found in  
26 the Periplasmic Loops (PL) - 1, 2, 3, and 6; Trans-membrane (TM) regions - 2, 4, 5, 7, 8,  
27 and 9; and Cytoplasmic Loops (CL) - 1 and 5. The association of Wzy<sub>Sf</sub> and Wzz<sub>Sf</sub> was  
28 investigated by transforming these mutated *wzy*<sub>Sf</sub> plasmids into a *wzy*<sub>Sf</sub> and *wzz*<sub>Sf</sub> deficient  
29 strain ( $\Delta wzy \Delta wzz$ ). Comparison of the LPS profiles in the  $\Delta wzy$  and  $\Delta wzy \Delta wzz$   
30 backgrounds identified Wzy<sub>Sf</sub> mutants whose polymerization activity was Wzz<sub>Sf</sub>-dependent.  
31 Colicin E2 and bacteriophage Sf6c sensitivities were consistent with the LPS profiles.  
32 Analysis of the expression levels of the Wzy<sub>Sf</sub>-GFP mutants in the  $\Delta wzy$  and  $\Delta wzy \Delta wzz$   
33 backgrounds identified a role for Wzz<sub>Sf</sub> in Wzy<sub>Sf</sub> stability. Hence, in addition to its role in  
34 regulating Oag modal chain length, Wzz<sub>Sf</sub> also affects Wzy<sub>Sf</sub> activity and stability.

35

36

37

38

## 39 Introduction

40 *Shigella flexneri* lipopolysaccharide (LPS) is crucial for pathogenesis **(1)**. LPS is exclusively  
41 located in the outer leaflet of the outer membrane (OM) and has three domains: 1) Lipid A -  
42 a hydrophobic domain which anchors LPS to the OM, 2) the core oligosaccharides - a non-  
43 repeating oligosaccharide domain, and 3) the O-antigen (Oag) polysaccharide - an  
44 oligosaccharide repeat domain **(1) (2)**. The complete LPS structure with Oag chains is  
45 termed smooth LPS (S-LPS). However, the LPS structure lacking the Oag is termed rough  
46 LPS (R-LPS), and LPS with a single Oag tetrasaccharide repeat unit (RU) attached to the  
47 Lipid A and core sugar is termed semi-rough LPS (SR-LPS) **(3)**. *S. flexneri* is subdivided  
48 into various serotypes depending on the differences in the composition of LPS Oag. So far  
49 there are 17 known serotypes of *S. flexneri* **(4)**. Except for *S. flexneri* serotype 6, the Oag of  
50 all other serotypes has the same polysaccharide backbone containing three L-rhamnose  
51 residues (Rha), and one *N*-acetylglucosamine (GlcNAc). This basic Oag structure is known  
52 as serotype Y. Addition of either glucosyl, O-acetyl, or phosphoethanolamine (PEtN) groups  
53 by various linkages to the sugars of the Y serotype tetrasaccharide repeat creates different  
54 *S. flexneri* serotypes **(5-7)**. Oag is the protective antigen as immunity against the *S. flexneri*  
55 infection is serotype specific **(8, 9)**. S-LPS confers resistance to complement **(10)** and  
56 colicins **(11, 12)**, and Y serotype Oag acts as a receptor to bacteriophage Sf6 **(13)**.

57

58 *S. flexneri* Oag biosynthesis occurs by the Wzy-dependent pathway. Most of the Oag  
59 biosynthesis genes (except *wecA*) of *S. flexneri* are located in the Oag biosynthesis locus  
60 between *galF* and *his* **(6, 14)**. *S. flexneri* Oag biosynthesis occurs on either side of the inner

61 membrane (IM). Initially N-acetylglucosamine phosphate (GlcNAc-1-P) is transferred from  
62 uridine diphosphate-GlcNAc (UDP-GlcNAc) by *WecA* to undecaprenol phosphate (Und-P)  
63 at the cytoplasmic side of the IM **(5, 15, 16)**. *RfbG* and *RfbF* then add Rhamnose (Rha)  
64 residues from thymidine diphospho-rhamnose (dTDP-Rha) to the GlcNAc **(3, 17)** to form  
65 the O unit. In the *Wzy*-dependent model of LPS assembly, the flippase protein *Wzx*  
66 translocates this O unit to the periplasmic side. At the periplasmic side, the O units are  
67 polymerized at the non-reducing end by the Oag polymerization protein *Wzy* via a block  
68 transfer mechanism to form the polymer. The chain length of the final Oag is regulated by  
69 the protein *Wzz* **(3, 18)**. Finally, the Oag ligase *WaaL* ligates the Oag chains to the  
70 previously synthesized core-lipid A. The *Lpt* proteins (*Lpt A-G*) then transport the LPS from  
71 the IM to the OM **(1, 19)**.

72

73 The Oag polymerization protein *Wzy<sub>Sf</sub>* is encoded by the *rfc/wzy* gene. *Wzy<sub>Sf</sub>* is a 43.7 kDa  
74 hydrophobic integral membrane protein. It has 12 transmembrane (TM) segments and two  
75 large periplasmic (PL) domains **(3, 18)**. Based on a topology model proposed by our group  
76 the amino and carboxy terminal ends are located on the cytoplasmic side of the IM. The  
77 wild type *wzy<sub>Sf</sub>* gene lacks a detectable ribosome binding site, has a low G+C %, and a high  
78 percentage of minor codons in the first 25 amino acids, contributing to low expression and  
79 poor detection of the protein **(3, 18)**.

80

81 Islam et al. (2011) performed extensive work on *Pseudomonas aeruginosa* *Wzy* (*Wzy<sub>Pa</sub>*)

82 and showed that both PL3 and PL5 of Wzy<sub>Pa</sub> contain RX<sub>10</sub>G motifs, which are important for  
83 the functioning of Wzy<sub>Pa</sub>. They also found several Arg residues within these two motifs are  
84 also important for Wzy<sub>Pa</sub> function **(20)**. However there is little sequence identity between  
85 Wzy<sub>Pa</sub> and Wzy<sub>Sf</sub>. So, it is not possible to predict the functional amino acid residues of  
86 Wzy<sub>Sf</sub> from another model.

87

88 Wzz is a member of the polysaccharide co-polymerase (PCP) family. *S. flexneri* has two  
89 types of Wzz - chromosomally encoded Wzz<sub>Sf</sub> and pHS-2 plasmid encoded Wzz<sub>pHS2</sub>. *S.*  
90 *flexneri* 2a has S-LPS with two types of modal chain length: short (S) type (11-17 Oag RUs)  
91 and very long (VL) type (>90 Oag RUs), and the S-type and VL-type Oag chain lengths are  
92 determined by Wzz<sub>Sf</sub> and Wzz<sub>pHS2</sub>, respectively. Controlling Oag chain length is crucial for  
93 bacterial virulence and loss of Wzz<sub>Sf</sub> mediated Oag modal chain length regulation affects  
94 virulence due to masking of the OM protein IcsA **(21, 22)**. Daniels and Morona (1999)  
95 showed that Wzz<sub>Sf</sub> forms a dimer *in vivo* and may oligomerise up to a hexamer **(23)**.  
96 Formation of these large complexes is consistent with the hypothetical complex formation  
97 between Wzz and other enzymes of the Oag biosynthesis pathway, including Wzy **(14, 24)**.  
98 Wzz<sub>Sf</sub> and Wzz<sub>pHS2</sub> compete for the available Wzy<sub>Sf</sub> **(25)**.

99

100 Woodward et al. (2010) showed that Wzz and Wzy are sufficient to determine the Oag  
101 modal chain length **(26)**. There are several proposed mechanisms for modal length control  
102 by Wzz and its association with Wzy: a molecular clock model was proposed by Bastin et

103 al. (1993) **(24)** and a molecular chaperone model was proposed by Morona et al. (1995)  
104 **(14)**. Tocilj et al. (2008) suggested that Wzz may form a scaffold and recruits Wzy **(27)**.  
105 However, there is no direct evidence to date on how these proteins are associated with  
106 each other in Oag polymerization and chain length control.

107

108 In this study we were able to overexpress and detect Wzy<sub>Sf</sub>-GFP expression in *S. flexneri*.  
109 We performed random mutagenesis on *wzy*<sub>Sf</sub> and following screening with colicin E2, for  
110 the first time identified amino acid residues important for Wzy<sub>Sf</sub> function. We classified the  
111 *wzy*<sub>Sf</sub> mutants based on their LPS profile. We were able to determine mutant protein  
112 expression levels, and also characterised the mutants depending on the phage and colicin  
113 sensitivities they conferred. These findings provided insight to Wzy structure and function.  
114 We further identified Wzz<sub>Sf</sub>-dependent Wzy<sub>Sf</sub> mutants, and identified a novel role for Wzz<sub>Sf</sub>  
115 in Wzy<sub>Sf</sub> Oag polymerization activity and stability, in addition to its role in regulating Oag  
116 modal chain length.

117

## 118 **Materials and Methods**

### 119 **Bacterial strains and plasmids**

120 The strains and plasmids used in this study are shown in Table 1.

121

## 122 **Growth media and growth conditions**

123 The growth media used were Luria-Bertani (LB) broth (10 g/liter tryptone, 5 g/liter yeast  
124 extract, 5 g/liter NaCl) and LB agar (LB broth, 15 g/liter bacto agar).

125 Unless otherwise stated strains were grown in LB broth with aeration for 18 h at 37°C, then  
126 diluted 1/20 into fresh LB broth and grown to mid-exponential phase (optical density at 600  
127 nm [OD<sub>600</sub>] of 0.4 - 0.6). Where required growth medium was supplemented with 0.2% (w/v)  
128 glucose to suppress protein expression. Before induction cells were centrifuged (2200 x g,  
129 SIGMA 3K15 table top centrifuge, 10 min, 4°C) and washed twice with LB broth to remove  
130 glucose. During induction conditions, 0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG)  
131 or 0.2% (w/v) or L-arabinose was added to cultures and grown for 20 h at 20°C. Antibiotics  
132 were added as required to the media at the following final concentrations: kanamycin (Km;  
133 50 µg/ml), and chloramphenicol (Cm; 25 µg/ml).

134

## 135 **Construction of expression vector and cloning of *wzy<sub>Sf</sub>***

136 Primers PN1\_*wzy<sub>Sf</sub>**KpnF* and PN2\_*wzy<sub>Sf</sub>**BamHR* (Supplementary Table S1) which  
137 incorporated *KpnI* and *BamHI* restriction sites, respectively, were used to amplify the  
138 previously mutated *wzy<sub>Sf</sub>* coding region (GenBank accession number X71970) in the  
139 pRMCD6 plasmid (Table 1), possessing three changes at codons 4, 9 and 23 (**18**). The rare  
140 codons 4, 9 and 23 are present in the translation initiation site of *Wzy<sub>Sf</sub>* and causes lower  
141 expression of the wild-type *Wzy<sub>Sf</sub>*. The codons ATA, ATA and AGA at 4, 9 and 23 were  
142 changed to ATT, ATT and CGT, respectively, and resulted in increased expression of *Wzy<sub>Sf</sub>*



143 **(18)**. Following restriction digestion with enzymes *Bam*HI and *Kpn*l, the amplified *wzy<sub>Sf</sub>* was  
144 ligated into similarly digested pWaldo-TEV-GFP **(28)**, resulting in the plasmid pWaldo-  
145 *wzy<sub>Sf</sub>*-TEV-GFP (denoted as pRMPN1). PCR, restriction enzyme digestion, agarose gel  
146 electrophoresis, ligation, and transformation were performed as described previously **(3,**  
147 **14)**.

148

### 149 **Wzy<sub>Sf</sub> expression in Lemo21(DE3) and In-gel fluorescence**

150 For Wzy<sub>Sf</sub> expression in Lemo21(DE3) cells (Table 1), strains were induced with IPTG and  
151 the over-expressed Wzy<sub>Sf</sub>-GFP fusion protein was detected by In-gel fluorescence following  
152 the method of Drew et al. (2006) **(29)** with some modifications.  $5 \times 10^8$  cells were harvested  
153 from the induced culture and washed twice in 200  $\mu$ l phosphate buffered-saline (PBS). The  
154 pellet was re-suspended in 20  $\mu$ l PBS and 20  $\mu$ l Buffer A (200 mM Tris-HCl [pH 8.8], 20%  
155 [v/v] glycerol, 5 mM EDTA [pH 8.0], 0.02% [w/v] bromophenol blue, 4% [w/v] SDS, and 0.05  
156 M DDT) was then added to the cell suspension. The solubilized cell suspension was  
157 incubated at 37°C for 5 min. Samples were then electrophoresed on SDS 15% (w/v)  
158 polyacrylamide gels (SDS-15% PAGE) and BenchMark™ Pre-Stained Protein Ladder  
159 (Invitrogen) was used as a molecular mass standard. The gel was rinsed with distilled water  
160 and fluorescent imaging of the gel was performed to detect Wzy<sub>Sf</sub>-GFP protein expression  
161 with a Bio-Rad Gel Doc™ XR + System using Image Lab software (excitation at 485 nm  
162 and emission at 512 nm).

163

164 **LPS method**

165 LPS was prepared as described previously **(30, 31)**. To prepare LPS samples,  $1 \times 10^9$  cells  
166 were harvested and resuspended in lysing buffer (Buffer B - 10% [w/v] glycerol, 2% [w/v]  
167 SDS, 4% [w/v]  $\beta$ -mercaptoethanol, 0.1% [w/v] bromophenol blue, 1 M Tris-HCl, pH 7.6) and  
168 incubated with 2  $\mu$ g/ml of proteinase K for approximately 16 h. The LPS samples were then  
169 electrophoresed on a SDS-15% PAGE for 16 to 18 h at 12 mA. The gel was stained with  
170 silver nitrate, developed with formaldehyde **(30)**.

171

172 **Random mutagenesis**

173 Random mutagenesis of *wzy<sub>Sf</sub>* was undertaken to obtain a wide range of *wzy<sub>Sf</sub>* mutations in  
174 a non-selected manner. For PCR random mutagenesis the *wzy<sub>Sf</sub>* coding region in plasmid  
175 pRMPN1 was mutagenized by an error prone DNA polymerase using the GeneMorp II EZ-  
176 Clone Domain Mutagenesis Kit (Catalog # 200552, Stratagene) as per the manufacturer's  
177 instructions with the primers PN1\_*wzy<sub>Sf</sub>KpnF* and PN2\_*wzy<sub>Sf</sub>BamHR* (Supplementary  
178 Table S1). Mutagenized plasmids were transformed into competent *E. coli* cells, XL10-Gold  
179 (Agilent Technologies). Plasmid DNA was then isolated from randomly chosen transformed  
180 mutated colonies and transformed into strain PNRM6 (Table 1). Colicin swab assays were  
181 performed to screen the mutants (See below). Plasmid DNA was isolated from putative  
182 mutants, transformed into XL10G, and subjected to DNA sequencing (AGRF, Adelaide,  
183 Australia).

184

### 185 **Construction of the strain RMA4437 ( $\Delta wzy \Delta wzz$ )**

186 The *S. flexneri* Y PE638  $\Delta wzy \Delta wzz$  mutant strain was constructed using allelic exchange  
187 mutagenesis **(14)** to inactivate the *wzz<sub>Sf</sub>* gene in RMM109 **(3)**. Initially, a tetracycline  
188 resistance (*tet<sup>R</sup>*) cartridge was inserted into the *Bgl*II site of pRMA577 **(14)** to inactivate  
189 *wzz<sub>Sf</sub>*, and the resulting pCACTUS-*wzz<sub>Sf</sub>::tet* (Table 1) plasmid was transformed into  
190 RMM109 via electroporation **(32)**. Allelic exchange mutagenesis was performed as  
191 previously described **(14)**. The *wzz<sub>Sf</sub>::tet<sup>R</sup>* mutation in the chromosome was confirmed by  
192 PCR with primers ET35 and ET36 (Supplementary Table S1) to give the PE638  $\Delta wzy \Delta wzz$   
193 mutant RMA4337.

194

### 195 **Detection of Wzy<sub>Sf</sub> expression in *S. flexneri***

196 For the detection of Wzy<sub>Sf</sub> expression in *S. flexneri*, cells were harvested from the 50 ml  
197 0.2% (w/v) L-arabinose induced culture by centrifugation (9800 x g, Beckman J2-21M  
198 Induction Drive Centrifuge, 10 min, 4 °C) and the cell pellet was resuspended in 4 ml  
199 sonication buffer (Buffer C, 20 mM Tris-HCl, 150 mM NaCl, pH 7.5). The mixture was then  
200 lysed by sonication, followed by centrifugation (2200 x g, SIGMA 3K15 table top centrifuge,  
201 10 min, 4 °C) to remove debris. Ultracentrifugation was performed in a Beckman Coulter  
202 Optima L-100 XP bench top ultracentrifuge (126000 x g for 1 h at 4 °C) to isolate the whole  
203 membrane (WM) fraction. The WM fraction was resuspended in PBS and then solubilized in  
204 Buffer A. Solubilized WM fraction from 3 X 10<sup>8</sup> cells was electrophoresed on a SDS-15%  
205 PAGE. The gel was rinsed with distilled water and In-gel imaging was performed as

206 described above. Loading was checked by staining the gel with Coomassie Blue R-250.  
207 The intensity of Wzy<sub>Sf</sub>-GFP expression for mutant and control strains was measured by Fiji  
208 image processing package (<http://fiji.sc/Fiji>) and the percent relative Wzy<sub>Sf</sub>-GFP intensity for  
209 each mutant strain was measured by comparing the Wzy<sub>Sf</sub>-GFP intensity of each mutant  
210 strain with Wzy<sub>Sf</sub>-GFP intensity in the control strain PNRM13.

211

### 212 **Colicin sensitivity assay**

213 For the colicin sensitivity assay a solution of purified His<sub>6</sub>-ColE2 (ColE2) with an initial  
214 concentration of 1 mg/ml was used (11).

215

### 216 *ColE2 swab assay*

217 A two fold serial dilution of 10<sup>-3</sup> dilution of ColE2 was swabbed onto antibiotic selective LB  
218 agar plates containing 0.2% (w/v) L-arabinose with a cotton swab. Plates were left to dry for  
219 1 h at room temperature (RT). Individual 0.2% (w/v) L-arabinose induced mutant and  
220 control LB cultures were then swabbed perpendicular to the ColE2 streak and plates were  
221 left to dry for another 1 h at RT. Plates were then incubated for 16 h at 37°C. The  
222 susceptibility of the mutant strains compared to the control strain was recorded and the  
223 image was taken using a Canon scanner (CanoScan 9000F) against a dark background.

224

225 *ColE2 spot assay*

226 The spot assay was performed using the serial dilutions of ColE2. 100  $\mu$ l of the individual L-  
227 arabinose induced mutant and control strain cultures were spread onto LB agar plates with  
228 appropriate antibiotics and 0.2% (w/v) L-arabinose. Plates were left to dry for 2 h at RT. A  
229 2-fold serial dilution of  $10^{-3}$  dilution of ColE2 (denoted as Neat or [N]) was spotted on the  
230 dried plates, and plates were left to dry for another 3 h at RT. Plates were then incubated  
231 for 18 h at 37°C. The end point of the killing zones of mutant strains was compared with the  
232 controls. Images were recorded as above.

233

234 **Bacteriophage sensitivity assay**

235 Procedures of phage propagation and phage stock preparation have been described  
236 previously (**3, 33**). The concentration of the bacteriophage Sf6c stock used was  $8.6 \times 10^7$   
237 p.f.u./ ml. Mutant and control strains were grown and induced with 0.2% (w/v) L-arabinose.  
238 100  $\mu$ l of the individual mutant and control LB cultures were spread onto LB agar plates  
239 with appropriate antibiotics and 0.2% (w/v) L-arabinose. Plates were left to dry for 2 h at RT.  
240 Serial dilutions of the bacteriophage Sf6c stock (undiluted bacteriophage Sf6c stock was  
241 denoted as N) were spotted on the dried plates and plates were dried for a further 3 h at  
242 RT. The plates were incubated for 18 h at 37°C. Phage sensitivity of the test strains were  
243 compared with the controls. Images were recorded as above.

244

## 245 Results

### 246 Construction of a *Wzy<sub>Sf</sub>*-GFP expression plasmid

247 A suitable expression system was constructed to express *wzy<sub>Sf</sub>* and to detect *Wzy<sub>Sf</sub>* by  
248 fusion to Green Fluorescent Protein (GFP) **(29)**. *S. flexneri* 2457T 2a *wzy<sub>Sf</sub>* with three  
249 modified codons at positions 4, 9, 23 in pRMCD6 plasmid **(18)** was PCR amplified and  
250 ligated into pWaldo-TEV-GFP (Table 1) (See Materials and Methods). To confirm the  
251 construct was able to express *Wzy<sub>Sf</sub>*-GFP-His<sub>8</sub> protein, pWaldo-*wzy<sub>Sf</sub>*-TEV-GFP-His<sub>8</sub>  
252 (denoted as pRMPN1) was transformed into Lemo21(DE3) cells. Whole cell In-gel  
253 fluorescence samples were then prepared from PNRM15 (Lemo21(DE3), [pRMPN1) and  
254 fluorescent imaging of the gel detected a fluorescent band at approximately 64 kDa which  
255 corresponded to the predicted size of the *Wzy<sub>Sf</sub>*-GFP protein (Supplementary Fig. S1, lane  
256 1), indicating that the construct was able to express *Wzy<sub>Sf</sub>*-GFP.

257

### 258 Complementation of *wzy<sub>Sf</sub>* deficiency

259 A complementation assay was performed to confirm the functionality of *Wzy<sub>Sf</sub>*-GFP. For this  
260 assay pRMPN1 was co-transformed along with pAC/pBADT7-1 **(34)** into a *wzy<sub>Sf</sub>* deficient  
261 strain RMM109 **(3)**. RMM109 has a frameshift mutation at position 9214 in the *wzy<sub>Sf</sub>* gene  
262 that results in premature termination of *Wzy<sub>Sf</sub>* synthesis **(3)**. pAC/pBADT7-1 encodes T7  
263 RNA polymerase which drives the expression of *wzy<sub>Sf</sub>*-GFP in pRMPN1. LPS samples were  
264 prepared from these control strains. The silver-stained gel showed that PNRM6 (RMM109,  
265 pAC/pBADT7-1) had a SR-LPS profile (Fig. 1, lane 3). But the PNRM13 (PNRM6,

266 pRMPN1) had a S-LPS profile (Fig. 1, lane 5). Hence, pRMPN1 was able to complement  
267 the *wzy<sub>Sf</sub>* mutation in RMM109, and the LPS profile resembled that of the wild type strain  
268 PE638 (Fig. 1, lane 2).

269

### 270 **Random mutagenesis of *wzy<sub>Sf</sub>***

271 Nothing is known about the residues important for *Wzy<sub>Sf</sub>* function, and there is little  
272 sequence identity between *Wzy* proteins of different bacterial species. Hence, it is difficult  
273 to predict the functional amino acid residues of the *S. flexneri* *Wzy<sub>Sf</sub>*. To obtain insight into  
274 the *Wzy<sub>Sf</sub>* residues needed for function, *wzy<sub>Sf</sub>* coding region in plasmid pRMPN1 was  
275 subjected to random mutagenesis using an error prone DNA polymerase (See Materials  
276 and Methods). The resulting mutagenized plasmid library was transformed into PNRM6. We  
277 screened the transformants to find mutants using ColE2. The basis for this is that the R-  
278 LPS strains are more susceptible to the killing by colicins than the S-LPS strains (**12**), and  
279 we recently found that there is a strong correlation between LPS Oag modal chain length  
280 and susceptibility to ColE2 (**11**). A ColE2 swab assay (See Materials and Methods) was  
281 used to screen and detect mutants that had a different sensitivity to ColE2 compared to the  
282 positive control strain PNRM13 (Supplementary Table S2). Interestingly the wild type strain  
283 PE638 was slightly more resistant to ColE2 compared to the complemented positive control  
284 strain PNRM13 (Supplementary Table S2) (Table 2). The *wzy<sub>Sf</sub>* mutant RMM109 (SR-LPS)  
285 was highly sensitive to ColE2 (Supplementary Table S2) (Table 2). Transformants that were  
286 either more resistant or more sensitive to ColE2 than PNRM13 were selected  
287 (Supplementary Table S2), and the plasmids isolated and transformed into the XL10G

288 strain. Plasmid DNA from these isolates was subjected to DNA sequencing to identify  
289 mutational alterations in *wzy<sub>Sf</sub>*. The *wzy<sub>Sf</sub>* mutants had the following substitutions: P352H,  
290 V92M, Y137H, L214I, G130V, N147K, P165S, L191F, C60F, L49F/T328A, L28V, N86K,  
291 F54C, F52Y, L111I, G82C, and F52C/I242T (Supplementary Table S3). The mutations  
292 were present in PL1, 2, 3, and 6; TM 2, 4, 5, 7, 8, and 9; and Cytoplasmic Loops (CL) 1 and  
293 5 of the *Wzy<sub>Sf</sub>* topology map (summarized in Fig. 2 and Table 2). After sequence  
294 confirmation, the mutated plasmids were transformed into PNRM6 (Table 1) for detailed  
295 characterization.

296

### 297 **LPS phenotype conferred by *Wzy<sub>Sf</sub>* mutants**

298 The effect of mutations on *Wzy<sub>Sf</sub>* LPS Oag polymerization activity was determined by SDS-  
299 PAGE and silver staining. Following comparison of the resulting degree of LPS Oag  
300 polymerization of the mutant strains with the relevant positive control PNRM13, the mutants  
301 were grouped into four different phenotypic classes: A, B, C, and D (Fig. 3 and  
302 Supplementary Fig. S2). Three of the 17 mutants had reduced degrees of polymerization  
303 compared to PNRM13 and were classified as class A. Class A mutants had following  
304 alterations in *Wzy<sub>Sf</sub>*: P352H, V92M, Y137H (Fig. 3, lanes 2-4). One mutant (with L214I  
305 alteration in *Wzy<sub>Sf</sub>*) exhibited LPS banding pattern with only a few Oag RUs and was  
306 classified as Class B (Fig. 3, lane 5). Another mutant had SR-LPS (with a G130V alteration  
307 in *Wzy<sub>Sf</sub>*) and was categorized into Class C (Fig. 3, lane 6). The other 12 mutants conferred  
308 a LPS profile nearly similar to the positive control PNRM13 and were classified as Class D.  
309 Members of this class had the following mutations: N147K, P165S, L191F, C60F,



310 L49F/T328A, L28V, N86K, F54C, F52Y, L111I, G82C, F52C/I242T (Fig. 3, lanes 7-10 and  
311 Supplementary Fig. S2, Lanes 1-8). For rest of the paper the mutant Wzy<sub>Sf</sub> proteins will be  
312 referred according to their conferred LPS class.

313

#### 314 **Wzz<sub>Sf</sub> dependence**

315 Since the Wzy-dependent model of LPS assembly suggests a potential interaction between  
316 Wzy and Wzz, we investigated if the LPS profile conferred by mutated Wzy<sub>Sf</sub> proteins was  
317 dependent on the presence of Wzz<sub>Sf</sub>. All the plasmids encoding mutated Wzy<sub>Sf</sub> proteins  
318 were transformed into RMA4337 carrying pAC/pBADT7-1 (strain PNRM126) (Table 1).  
319 RMA4337 is a *wzy<sub>Sf</sub>* and *wzz<sub>Sf</sub>* double mutant. The LPS profiles conferred in the PNRM126  
320 background ( $\Delta wzy \Delta wzz$ ) were directly compared with the LPS profile conferred in the  $\Delta wzy$   
321 background (PNRM6). The control strain PNRM134 (PNRM126 [pRMPN1]) had S-LPS  
322 without Oag modal chain length control (Fig. 4, lane 3) as expected, and was classified as  
323 Class E for the purpose of comparison. PNRM126 with mutated *wzy<sub>Sf</sub>* plasmids that  
324 conferred a Class A LPS profile in the  $\Delta wzy$  background had a Class E LPS profile similar  
325 to PNRM134, except PNRM126 expressing WzyP352H had LPS with few Oag RUs (Class  
326 B) (Fig. 4, lane 5). PNRM126 expressing WzyL214I had SR-LPS (Fig. 4, lane 11).  
327 However, in comparison PNRM6 ( $\Delta wzy$ ) expressing WzyL214I conferred a Class B LPS  
328 profile (Fig. 4, lane 10). PNRM126 with a mutated *wzy<sub>Sf</sub>* plasmid that conferred a Class C  
329 LPS profile in the  $\Delta wzy$  background (PNRM6 expressing G130V), had S-LPS without modal  
330 length control and a reduced degree of polymerization (designated Class F) compared to  
331 PNRM134 (Fig. 4, lane 13). PNRM126 with mutated *wzy<sub>Sf</sub>* plasmids from the strains with

332 Class D LPS profile in the  $\Delta wzy$  background, had Class E LPS profile, similar to PNRM134  
333 (Fig. 4, lanes 14-21 and Supplementary Fig. S3, lanes 1-16). Hence certain  $Wzy_{Sf}$  mutants  
334 conferred dramatically different LPS profiles depending on the presence and absence of  
335  $Wzz_{Sf}$ .

336

### 337 **ColE2 and bacteriophage Sf6c sensitivities**

338 To confirm the LPS profiles determined above using assays of LPS Oag function, the ColE2  
339 and bacteriophage Sf6c sensitivities of the mutant strains were investigated. ColE2  
340 sensitivity (summarized in Table 2) was determined by spot testing as described in the  
341 Materials and Methods. Strains RMM109, PNRM6, PNRM11, RMA4337, and PNRM126  
342 showed killing zones at a dilution of 1/256. The wild type strain PE638 was resistant to the  
343 highest concentration of ColE2 used. The relevant positive control strain in the  $\Delta wzy$   
344 background (PNRM13) showed a killing zone at a dilution of 1/2 but the relevant positive  
345 control strain in the  $\Delta wzy \Delta wzz$  background (PNRM134) was resistant to the tested highest  
346 concentration of ColE2. Strains conferring Class A LPS profile in the  $\Delta wzy$  background  
347 were sensitive to ColE2 (killing zone at 1/32 or 1/64). However,  $\Delta wzy \Delta wzz$  strains with  
348 mutated  $wzy_{Sf}$  plasmids conferring the Class A LPS profile in the  $\Delta wzy$  background were  
349 two-fold more sensitive to ColE2 (killing zone at 1/64 or 1/128) compared to the  $\Delta wzy$   
350 background. The  $\Delta wzy$  strain expressing  $Wzy_{L214I}$  (Class B) and the  $\Delta wzy \Delta wzz$  strain  
351 expressing  $Wzy_{L214I}$  (Class C) had similar ColE2 sensitivity (1/128). The strain with the  
352 Class C LPS profile ( $\Delta wzy$  expressing  $Wzy_{G130V}$ ) had the greatest sensitivity to ColE2  
353 (1/512), greater than RMM109 and the negative control strains (PNRM6, PNRM11,

354 PNRM126). However, the  $\Delta wzy \Delta wzz$  strain expressing WzyG130V (Class F) was more  
355 resistant (1/128) to ColE2 compared to the  $\Delta wzy$  background. Strains with Class D LPS  
356 profile in the  $\Delta wzy$  background were resistant to the tested highest concentration of ColE2,  
357 except  $\Delta wzy$  expressing WzyP165S showed slight sensitivity (1/4). Hence, almost all the  
358 strains with Class D LPS profile in the  $\Delta wzy$  background were more resistant to ColE2  
359 compared to PNRM13 and were similar to PE638. The  $\Delta wzy \Delta wzz$  strains with mutated  
360  $wzy_{Sf}$  plasmids from the strains with Class D LPS profile in the  $\Delta wzy$  background were  
361 more sensitive to ColE2 (killing zone at 1/8 to 1/64) compared to the control PNRM134  
362 ( $\Delta wzy \Delta wzz$  [pRMPN1]), suggesting they have slight defect in Oag polymerization in the  
363 absence of  $Wzz_{Sf}$ . Hence, ColE2 resistance correlated with degree of Oag polymerization  
364 and degree of LPS capping with Oag.

365

366 The bacteriophage Sf6c sensitivity of the strains (summarized in Table 2), carrying mutated  
367  $wzy_{Sf}$  plasmids, was determined by spot testing as described in the Materials and Methods.  
368 The SR-LPS strains RMM109, PNRM6, PNRM11, RMA4337, and PNRM126 were resistant  
369 to bacteriophage Sf6c. The S-LPS strains wild type PE638, and the controls PNRM13 and  
370 PNRM134 were bacteriophage Sf6c sensitive, and plaques were detected at  $10^{-6}$ ,  $10^{-5}$ , and  
371  $10^{-6}$  dilutions, respectively. Strains with Class A, B, and C LPS profiles in the  $\Delta wzy$   
372 background were resistant to the highest concentration of bacteriophage Sf6c tested and  
373 were similar to the strains with SR-LPS (RMM109, PNRM6, PNRM11, RMA4337, and  
374 PNRM126). Similarly, the  $\Delta wzy \Delta wzz$  strains with mutated  $wzy_{Sf}$  plasmids from the strains  
375 with Class A, B, and C LPS profiles in the  $\Delta wzy$  background were also resistant to the

376 highest concentration of bacteriophage Sf6c tested. Strains with Class D LPS profile in the  
377  $\Delta wzy$  background were bacteriophage Sf6c sensitive (plaques at  $10^{-6}$ ), except for the strain  
378 expressing WzyP165S was slightly less sensitive (plaque at  $10^{-5}$ ). Hence, the  
379 bacteriophage Sf6c sensitivity of the strains with Class D LPS profile in the  $\Delta wzy$   
380 background was greater than PNRM13 and similar to PE638.  $\Delta wzy \Delta wzz$  strains with  
381 mutated  $wzy_{Sf}$  plasmids from the strains with Class D LPS profile in the  $\Delta wzy$  background  
382 were more resistant to bacteriophage Sf6c compared to the  $\Delta wzy$  background. Although  
383 they have a Class E LPS profile, similar to PNRM134, they were more resistant to  
384 bacteriophage Sf6c than PNRM134. Hence, bacteriophage Sf6c correlated with degree of  
385 Oag polymerization, and degree of LPS capping with Oag.

386

### 387 **Wzy<sub>Sf</sub> expression level**

388 We determined the level of parental and mutant Wzy<sub>Sf</sub>-GFP expressed in  $\Delta wzy$  and  $\Delta wzy$   
389  $\Delta wzz$  *S. flexneri* strains. To measure the protein expression level of the mutants, In-gel  
390 fluorescence was performed and the % relative Wzy<sub>Sf</sub>-GFP expression was calculated (See  
391 Materials and Methods). The expression levels of different Wzy<sub>Sf</sub>-GFP mutants were  
392 compared with that of Wzy<sub>Sf</sub>-GFP in PNRM13 (100%). The Wzy<sub>Sf</sub>-GFP expression level in  
393 PNRM134 was less than PNRM13 (Fig. 5A and B, lane 2), having a relative Wzy<sub>Sf</sub>-GFP  
394 level of 17% (Table 2). In the  $\Delta wzy$  background most of the Wzy<sub>Sf</sub>-GFP mutants were  
395 expressed at a level less than 100% except the mutants L191F (Class D) had expression of  
396 162% (Fig. 5B, lane 7 and Table 2). However, in the  $\Delta wzy \Delta wzz$  background the relative  
397 Wzy<sub>Sf</sub>-GFP level of L191F was 64% (Fig. 5B, lane 8 and Table 2), which was less than the

398 control PNRM13. In the  $\Delta wzy$  background, the relative  $Wzy_{Sf}$ -GFP levels of P165S, L214I,  
399 and G130V were very low (7%, 1.4%, and 1.6% respectively) (Fig. 5B, lane 5; Fig. 5A,  
400 lanes 9 and 11; and Table 2). However, in the  $\Delta wzy \Delta wzz$  background P165S and G130V  
401 had relative  $Wzy_{Sf}$ -GFP levels of 125% and 28.50%, respectively (Fig. 5B, lane 6; Fig 5A,  
402 lane 12; and Table 2) but the relative  $Wzy_{Sf}$ -GFP level of L214I was almost not detectable  
403 at 0.03% (Fig. 5A, lane 10 and Table 2). In the  $\Delta wzy \Delta wzz$  background, the relative  $Wzy_{Sf}$ -  
404 GFP level of P165S was higher than the control PNRM13 (100%) (Fig. 5B, lane 6 and  
405 Table 2). These data indicates that expression of certain  $Wzy_{Sf}$  mutants were affected by  
406  $Wzz_{Sf}$ , but the effect was mutant specific.

407

## 408 Discussion

409 In this study, we constructed and characterized a collection of  $wzy_{Sf}$  mutants. We found that  
410 Cole2 screening was an effective method to detect  $wzy_{Sf}$  mutants conferring subtle effects  
411 on LPS structure (Table 2). The use of  $Wzy_{Sf}$ -GFP allowed comparison of the protein  
412 expression level of different mutants. We also found that bacteriophage Sf6c sensitivity was  
413 dependent on LPS phenotype structure. Strains with mutant  $Wzy_{Sf}$  conferring longer Oag  
414 chain and/or a greater degree of Oag polymerization were more sensitive to bacteriophage  
415 Sf6c; while bacteriophage Sf6c only infected strains with wild type (or nearly wild type) LPS,  
416 both in degree of Oag polymerization and apparent level of LPS capping with Oag chains.

417

418 Only a few studies have been conducted on Wzy proteins. During characterization of Wzy  
419 of *Francisella tularensis*, Kim et al. (2010) reported several amino acid residues important  
420 for Oag polymerization. Modification of these residues (G176, D177, G323, and Y324) led  
421 to a loss of Oag polymerization **(35)**. Islam et al. showed that the PL3 and PL5 of Wzy<sub>Pa</sub>  
422 have net positive and net negative charges respectively and they established their “catch-  
423 and-release” model **(20)**. However, for Wzy<sub>Sf</sub>, we found that at a physiological pH both the  
424 PL3 and PL5 possess net negative charge (pI of PL3 is 4.65 and PL5 is 5.09). In  
425 *Pseudomonas aeruginosa* PAO1 there is a uronic acid sugar in the Oag **(36)**, which is  
426 negatively charged. However, the Oag of Wzy<sub>Sf</sub> is neutral. So, the charged property of the  
427 substrate for Wzy<sub>Sf</sub> is different from the Wzy<sub>Pa</sub>. The RX<sub>10</sub>G motifs of the PL3 and PL5 of  
428 Wzy<sub>Pa</sub> **(20)** are also absent in Wzy<sub>Sf</sub>. However, both PL3 and PL5 of Wzy<sub>Sf</sub> contained RX<sub>15</sub>G  
429 motifs (starting from R164 in PL3 and R289 in PL5) (Fig. 2). So, perhaps a modified version  
430 of the “catch-and-release” mechanism **(20)** exists for *S. flexneri*. Moreover, addition of  
431 either glucosyl or O-acetyl groups or PEtN residue by various linkages to the sugars within  
432 the tetrasaccharide repeats of serotype Y creates 17 different serotypes of the *S. flexneri*  
433 **(5-7)**. As the polymerization of all these Oags is done by Wzy<sub>Sf</sub>, and we conclude that Wzy<sub>Sf</sub>  
434 must be quite flexible for its substrate recruitment. Due to scant homology between wzy  
435 proteins of different bacterial species, we were unable to create any directly comparable  
436 mutation in Wzy<sub>Sf</sub> with respect to other systems. This led us to perform random  
437 mutagenesis on wzy<sub>Sf</sub> followed by screening with ColE2.

438

439 The mutations we found are present in a wide region (PL1, 2, 3, 5, and 6; TM 2, 4, 5, 7, 8,  
440 and 9; and CL 1 and 5) of the  $Wzy_{Sf}$  topological model experimentally determined by  
441 Daniels et al. (1998) **(18)**. We were able to locate a number of mutations in the TM regions  
442 and interestingly the G130V mutation, which resulted in the complete loss of polymerization  
443 activity of  $Wzy_{Sf}$  in the  $\Delta wzy$  background, was also located in TM5. Topological models are  
444 not very accurate but due to a lack of crystal structure we used the  $Wzy_{Sf}$  topology model  
445 previously determined by our group to locate the mutational alterations. Furthermore, we  
446 reassessed our topological model using 5 different topology prediction programs  
447 (SPOCTOPUS, MEMSAT, HMMTOP, TOPCONS, and TMHMM) (Supplementary Table  
448 S4). The results showed that until trans-membrane (TM) region 6 all the programs are  
449 consistent with our topological model. Three of them also validate TM10 - TM11 of our  
450 topological model. So, the topological model of  $Wzy_{Sf}$  determined by our group is nearly  
451 consistent with the topological models predicted by the programs. The mutations, which  
452 resulted in the partial loss of polymerization in the  $\Delta wzy$  background, were V92M, Y137H,  
453 L214I, and P352H. Among them V92M and Y137H are present in the PL2 and TM5. These  
454 regions were validated by 5 of the programs. P352H is present in the PL6 and this region  
455 was validated by 3 of the programs (MEMSAT, HMMTOP, and TOPCONS). L214I is  
456 present in the TM8 and this region (amino acid 209 - 226) was different compared to the  
457 computer prediction (amino acid 227 - 247). However, G130V is present in the TM5, which  
458 was validated by 5 of the programs. Recently, Reddy et al. (2014) reported that different  
459 topology prediction programs are suitable for different families of proteins **(37)**. So, non-  
460 prediction of TM7 - TM9 by some programs does not invalidate the presence of these  
461 regions in our model.

462 In the  $\Delta wzy$  background, strains with the Class A LPS profile had S-LPS with reduced  
463 degree of Oag polymerization (Fig. 3, lanes 2-4), mutants with the Class B LPS profile had  
464 LPS with few Oag RUs (Fig. 3, lane 5), and the mutant with Class C LPS profile had SR-  
465 LPS (Fig. 3, lane 6). As a result the Class A mutants were more sensitive to ColE2 than  
466 PNRM13 and the Class B mutants were even more sensitive to ColE2 than the mutants  
467 with the Class A LPS profile. The mutant with Class C LPS had the highest ColE2  
468 sensitivity. From these three classes it is clear that the LPS with shorter Oag chains were  
469 more sensitive to ColE2. Strains with Class A, B, and C LPS profiles in the  $\Delta wzy$   
470 background were resistant to bacteriophage Sf6c. The lack of bacteriophage Sf6c  
471 sensitivity indicates that bacteriophage Sf6c only infects if the LPS has wild type or close to  
472 wild type level of Oag polymerization. In this study we found that the  $Wzy_{sf}$  mutants  
473 conferring the Class D LPS profile in the  $\Delta wzy$  background, had a similar level of Oag  
474 polymerization compared to the positive control strain PNRM13, as determined by SDS-  
475 PAGE and silver staining (Fig. 3, lanes 7-10 and Supplementary Fig. S2, lanes 1-8) but  
476 they were more resistant to ColE2 and more sensitive to bacteriophage Sf6c (Table 2)  
477 (except  $\Delta wzy$  strain with  $Wzy_{P165S}$ ). The ColE2 and bacteriophage Sf6c sensitivities of  
478 these strains were similar to wild type strain PE638. We conclude that the Oag  
479 polymerization activity of the mutants with Class D LPS profile in the  $\Delta wzy$  background, was  
480 similar to the wild type strain (PE638). Hence, the wild type  $Wzy_{sf}$ -GFP protein is not 100%  
481 active, and the mutant proteins conferring the Class D LPS profile are more active and/or  
482 are better exported or folded or assembled to the IM. The level of Oag polymerization of the  
483 strains with Class D LPS profile was more than PNRM13, although this was not



484 distinguishable by silver staining. Hence, the ColE2 assay was more sensitive than silver  
485 staining and SDS-PAGE in determining the degree of Oag polymerization.

486

487 Mutation in *wzz* resulted in Oag without modal chain length control in different organisms  
488 **(14, 24)**. Recently, Kenyon and Reeves showed that *Wzy* of *Yersinia pseudotuberculosis*  
489 also needs *Wzz* for complete Oag polymerization **(38)**. Here we examined the  
490 polymerization activity of different *Wzy*<sub>Sf</sub> mutants in the absence of *Wzz*<sub>Sf</sub>. In the  $\Delta wzy \Delta wzz$   
491 background, the strains with mutated *wzy*<sub>Sf</sub> plasmids from the strains having Class B LPS  
492 profiles in the  $\Delta wzy$  background had a SR-LPS profile, and ColE2 and bacteriophage Sf6c  
493 sensitivities were similar to the  $\Delta wzy$  background. Interestingly, the  $\Delta wzy \Delta wzz$  strain with  
494 *Wzy*G130V had S-LPS without modal length control (Class F) where as the  $\Delta wzy$  strain  
495 with *Wzy*G130V had SR-LPS (Class C) and this correlated with an increased resistance to  
496 ColE2. In the  $\Delta wzy \Delta wzz$  background, strains with a Class E LPS profile (S-LPS without  
497 modal length control) had increased sensitivity to ColE2 and increased or similar resistance  
498 to bacteriophage Sf6c compared to PNRM134 ( $\Delta wzy \Delta wzz$  [pRMPN1]) and when in the  
499  $\Delta wzy$  background (strains with Class A and Class D LPS profiles) (Table 2). We speculate  
500 that these strains (strains with a Class E LPS profile) had subtle alterations in the level of  
501 Oag polymerization and/or capping of LPS with Oag, and were unable to act efficiently as a  
502 bacteriophage Sf6c receptor, and correspondingly were also more sensitive to ColE2. It is  
503 known that phage adsorption to the cells of *Escherichia coli* K12 increases with increase in  
504 density of receptor protein at the cell surface **(39)**. Based on our study, the relationship  
505 between ColE2 and Oag density/concentration seems linear. Decreasing Oag progressively

506 increases sensitivity to ColE2. However, the relationship between bacteriophage Sf6c and  
507 Oag density/concentration seems non-linear. Decreasing Oag rapidly decreases sensitivity  
508 to bacteriophage Sf6c. This may be because bacteriophage Sf6c interaction with its  
509 receptor is complex and most likely requires multi-receptor binding to bacteriophage Sf6c  
510 tail spike proteins (TSPs) to achieve irreversible binding and hence activation of  
511 bacteriophage Sf6c.

512

513 According to the proposed molecular clock model, Wzz acts as a molecular clock and  
514 regulates Wzy activity between two states: “E” or extension state favors polymerization and  
515 “T” or transfer state favors the ligation reaction **(24)**. The molecular chaperone model  
516 describes Wzz as a typical molecular chaperone, which regulates the overall ratio of Wzy  
517 and WaaL in a complex, and controls the enzyme kinetics of the ligation reaction to define  
518 the modality **(14)**. However, Woodward et al. (2010) suggests that there is an interaction  
519 between Wzy and Wzz and they showed that these proteins are enough to shape the Oag  
520 modal chain length **(26)**. Islam et al. (2013) suggested that the chain length of the Oag is  
521 determined by the interaction of Wzz and Wzy **(40)**. Recent work of Taylor et al. (2013) also  
522 suggested the direct interaction of Wzz and Wzy in the Oag biosynthesis pathway **(41)**. In  
523 this study, for the first time we were able to give an insight in the association of Wzy<sub>Sf</sub> and  
524 Wzz<sub>Sf</sub> in the Oag biosynthesis. We found Wzy<sub>Sf</sub> mutants where polymerization activity was  
525 dependent on Wzz<sub>Sf</sub> (WzyP352H and WzyL214I), and some other mutants where  
526 polymerization activity was repressed in the presence of Wzz<sub>Sf</sub> (WzyV92M, WzyY137H, and  
527 WzyG130V). The  $\Delta wzy \Delta wzz$  strain with WzyV92M or WzyY137H had S-LPS without

528 modal length control (Class E) but in the  $\Delta wzy$  background, they showed Class A LPS  
529 profile (a greatly reduced degree of Oag polymerization) (Fig 4, lanes 6-7 and lanes 8-9).  
530 The  $\Delta wzy$  strain with WzyG130V had Class C LPS profile (SR-LPS) but remarkably the  
531  $\Delta wzy \Delta wzz$  strain with WzyG130V had S-LPS without modal length control albeit with a  
532 reduced degree of polymerization (Class F) (Fig 4 lanes 12-13). Oag polymerization by  
533 these Wzy<sub>Sf</sub> mutants was repressed by Wzz<sub>Sf</sub>, in the  $\Delta wzy_{Sf}$  background; their LPS had  
534 shorter Oag chains. The  $\Delta wzy$  strain with WzyP352H had Class A LPS profile, and the  
535  $\Delta wzy$  strain with WzyL214I had Class B LPS profile but in the  $\Delta wzy/\Delta wzy$  background they  
536 had shorter Oag chains (Class B and C respectively) compared to the  $\Delta wzy$  background  
537 (Fig. 4, lanes 4-5 and 4 lanes 10-11). So, these Wzy<sub>Sf</sub> mutants need Wzz<sub>Sf</sub> for their Oag  
538 polymerization activity. These findings suggest that Wzz<sub>Sf</sub> is associated with Wzy<sub>Sf</sub> not only  
539 for Oag modal chain length control but also for polymerization activity, and amino acids  
540 V92, G130, Y137, L214, and P352 have role in the association of Wzy<sub>Sf</sub> and Wzz<sub>Sf</sub> during  
541 the Oag polymerization mediated by Wzy<sub>Sf</sub>.

542

543 The relative Wzy<sub>Sf</sub>-GFP level in PNRM134 ( $\Delta wzy \Delta wzz$ ) was lower than in PNRM13 ( $\Delta wzy$ )  
544 (Fig. 5A and B, lanes 1-2), suggesting that the wild type Wzy<sub>Sf</sub>-GFP had better expression  
545 in the presence of Wzz<sub>Sf</sub>. Wzy<sub>Sf</sub> mutants conferring Class A LPS profile ( $\Delta wzy$  background)  
546 had Wzy<sub>Sf</sub>-GFP levels less than the Wzy<sub>Sf</sub>-GFP in PNRM13 (Fig. 5A, lanes 3, 5, 7 and  
547 Table 2). WzyL214I was not detectable either in the  $\Delta wzy$  (Class B) or  $\Delta wzy \Delta wzz$  (Class  
548 C) backgrounds (Fig. 5A, lanes 9-10 and Table 2). Hence, amino acid L214 is important for  
549 Wzy<sub>Sf</sub>-GFP production. WzyG130V was not detectable in the  $\Delta wzy$  background (Class C)

550 but was detected in the  $\Delta wzy \Delta wzz$  background (Class F) (Fig. 5A, lanes 11-12 and Table  
551 2). Except for the strain  $\Delta wzy$  with WzyL191F, all the mutants with Class D LPS profile  
552 ( $\Delta wzy$  background) had a lower protein expression level than Wzy<sub>Sf</sub>-GFP in PNRM13 (Fig.  
553 5B and Table 2) by some unknown mechanism. However, the mutants with Class D LPS  
554 profile ( $\Delta wzy$  background) had S-LPS and were more resistant to ColE2 and more sensitive  
555 to bacteriophage Sf6c than PNRM13. In the  $\Delta wzy \Delta wzz$  background WzyL191F had an  
556 expression level less than Wzy<sub>Sf</sub>-GFP in PNRM13 (Fig. 5B, lane 8 and Table 2). WzyP165S  
557 was not detectable in PNRM6 ( $\Delta wzy$ ) but strain PNRM126 ( $\Delta wzy \Delta wzz$ ) with WzyP165S  
558 present at a greater level than Wzy<sub>Sf</sub>-GFP in PNRM13 (Fig. 5B, lanes 5-6 and Table 2).  
559 Apparently there are more than one underlying mechanism for the Class D ( $\Delta wzy$   
560 background) to Class E ( $\Delta wzy \Delta wzz$  background) LPS profile conversion. Some of the  
561 mutations (P165S and G130V) resulted in decreased Wzy<sub>Sf</sub>-GFP levels in the presence of  
562 Wzz<sub>Sf</sub>. This suggested that the presence of Wzz<sub>Sf</sub> destabilizes WzyP165S and WzyG130V,  
563 which resulted in lower Wzy<sub>Sf</sub>-GFP levels. The mutation L191F resulted in decreased  
564 Wzy<sub>Sf</sub>-GFP level in the absence of Wzz<sub>Sf</sub>. So, in this case Wzz<sub>Sf</sub> stabilizes the protein  
565 WzyL191F resulting in better Wzy<sub>Sf</sub>-GFP expression. This finding suggests that G130,  
566 P165, and L191 are important for the stabilization of Wzy<sub>Sf</sub> through interaction with Wzz<sub>Sf</sub>.

567

568 In conclusion, our findings identified amino acid residues on the Wzy<sub>Sf</sub> important for its  
569 polymerization function and interaction with Wzz<sub>Sf</sub>. Residues, which are important for the  
570 polymerization and interaction of Wzz<sub>Sf</sub> and Wzy<sub>Sf</sub> are present in the PL 2, 6 and TM 5, 8.  
571 These regions may contribute in the interaction of Wzy<sub>Sf</sub> with substrates and also in the

572 interaction with Wzz<sub>Sf</sub>. We identified a number of amino acids (G130, P165, L191), which  
573 are important for the stabilization of Wzy<sub>Sf</sub> in association with Wzz<sub>Sf</sub>. Hence, our data  
574 suggested that Wzz<sub>Sf</sub> also has a role in Wzy<sub>Sf</sub> stability.

575

## 576 **Acknowledgements**

577 We thank Dr. Daniel O. Daley for the pWaldo-TEV-GFP plasmid. Funding for this work is  
578 provided by a program grant to RM from the National Health and Medical Research Council  
579 (NHMRC) of Australia. P.N. is the recipient of an international postgraduate research  
580 scholarship from the University of Adelaide.

581

## 582 **References**

- 583 1. **Sperandeo, P., G. Deho, and A. Polissi.** 2009. The lipopolysaccharide transport  
584 system of Gram-negative bacteria. *Biochim. Biophys. Acta* **1791**:594-602.
- 585 2. **Raetz, C. R., and C. Whitfield.** 2002. Lipopolysaccharide endotoxins. *Annu. Rev.*  
586 *Biochem.* **71**:635-700.
- 587 3. **Morona, R., M. Mavris, A. Fallarino, and P. A. Manning.** 1994. Characterization of  
588 the *rfc* region of *Shigella flexneri*. *J. Bacteriol.* **176**:733-747.
- 589 4. **Sun, Q., R. Lan, Y. Wang, J. Wang, Y. Wang, P. Li, P. Du, and J. Xu.** 2013.  
590 Isolation and genomic characterization of Sfl, a serotype-converting bacteriophage of  
591 *Shigella flexneri*. *BMC Microbiol.* **13**:39.

- 592 5. **Wang, X., C. Zhang, F. Shi, and X. Hu.** 2010. Purification and characterization of  
593 lipopolysaccharides. *Subcell. Biochem.* **53**:27-51.
- 594 6. **Allison, G. E., and N. K. Verma.** 2000. Serotype-converting bacteriophages and O-  
595 antigen modification in *Shigella flexneri*. *Trends Microbiol.* **8**:17-23.
- 596 7. **Sun, Q., Y. A. Knirel, R. Lan, J. Wang, S. N. Senchenkova, D. Jin, A. S.**  
597 **Shashkov, S. Xia, A. V. Perepelov, Q. Chen, Y. Wang, H. Wang, and J. Xu.** 2012.  
598 A novel plasmid-encoded serotype conversion mechanism through addition of  
599 phosphoethanolamine to the O-antigen of *Shigella flexneri*. *PLoS One* **7**:e46095.
- 600 8. **Jennison, A. V., and N. K. Verma.** 2004. *Shigella flexneri* infection: pathogenesis  
601 and vaccine development. *FEMS Microbiol. Rev.* **28**:43-58.
- 602 9. **Stagg, R. M., S. S. Tang, N. I. Carlin, K. A. Talukder, P. D. Cam, and N. K.**  
603 **Verma.** 2009. A novel glucosyltransferase involved in O-antigen modification of  
604 *Shigella flexneri* serotype 1c. *J. Bacteriol.* **191**:6612-6617.
- 605 10. **Hong, M., and S. M. Payne.** 1997. Effect of mutations in *Shigella flexneri*  
606 chromosomal and plasmid-encoded lipopolysaccharide genes on invasion and  
607 serum resistance. *Mol. Microbiol.* **24**:779-791.
- 608 11. **Tran, E. N., M. Papadopoulos, and R. Morona.** 2014. Relationship between O-  
609 antigen chain length and resistance to colicin E2 in *Shigella flexneri*. *Microbiology*  
610 **160**:589-601.
- 611 12. **van der Ley, P., P. de Graaff, and J. Tommassen.** 1986. Shielding of *Escherichia*  
612 *coli* outer membrane proteins as receptors for bacteriophages and colicins by O-  
613 antigenic chains of lipopolysaccharide. *J. Bacteriol.* **168**:449-451.

- 614 13. **Lindberg, A. A., R. Wollin, P. Gemski, and J. A. Wohlhieter.** 1978. Interaction  
615 between bacteriophage Sf6 and *Shigella flexneri*. J. Virol. **27**:38-44.
- 616 14. **Morona, R., L. van den Bosch, and P. A. Manning.** 1995. Molecular, genetic, and  
617 topological characterization of O-antigen chain length regulation in *Shigella flexneri*.  
618 J. Bacteriol. **177**:1059-1068.
- 619 15. **Liu, D., R. A. Cole, and P. R. Reeves.** 1996. An O-antigen processing function for  
620 Wzx (RfbX): a promising candidate for O-unit flippase. J. Bacteriol. **178**:2102-2107.
- 621 16. **Guo, H., W. Yi, J. K. Song, and P. G. Wang.** 2008. Current understanding on  
622 biosynthesis of microbial polysaccharides. Curr. Top. Med. Chem. **8**:141-151.
- 623 17. **Macpherson, D. F., P. A. Manning, and R. Morona.** 1995. Genetic analysis of the  
624 *rfbX* gene of *Shigella flexneri*. Gene **155**:9-17.
- 625 18. **Daniels, C., C. Vindurampulle, and R. Morona.** 1998. Overexpression and  
626 topology of the *Shigella flexneri* O-antigen polymerase (Rfc/Wzy). Mol. Microbiol.  
627 **28**:1211-1222.
- 628 19. **Ruiz, N., L. S. Gronenberg, D. Kahne, and T. J. Silhavy.** 2008. Identification of two  
629 inner-membrane proteins required for the transport of lipopolysaccharide to the outer  
630 membrane of *Escherichia coli*. Proc. Natl. Acad. Sci. U. S. A. **105**:5537-5542.
- 631 20. **Islam, S. T., A. C. Gold, V. L. Taylor, E. M. Anderson, R. C. Ford, and J. S. Lam.**  
632 2011. Dual conserved periplasmic loops possess essential charge characteristics  
633 that support a catch-and-release mechanism of O-antigen polymerization by Wzy in  
634 *Pseudomonas aeruginosa* PAO1. J. Biol. Chem. **286**:20600-20605.

- 635 21. **Morona, R., C. Daniels, and L. Van Den Bosch.** 2003. Genetic modulation of  
636 *Shigella flexneri* 2a lipopolysaccharide O antigen modal chain length reveals that it  
637 has been optimized for virulence. *Microbiology* **149**:925-939.
- 638 22. **Morona, R., and L. Van Den Bosch.** 2003. Lipopolysaccharide O antigen chains  
639 mask lcsA (VirG) in *Shigella flexneri*. *FEMS Microbiol. Lett.* **221**:173-180.
- 640 23. **Daniels, C., and R. Morona.** 1999. Analysis of *Shigella flexneri* Wzz (Rol) function  
641 by mutagenesis and cross-linking: wzz is able to oligomerize. *Mol. Microbiol.* **34**:181-  
642 194.
- 643 24. **Bastin, D. A., G. Stevenson, P. K. Brown, A. Haase, and P. R. Reeves.** 1993.  
644 Repeat unit polysaccharides of bacteria: a model for polymerization resembling that  
645 of ribosomes and fatty acid synthetase, with a novel mechanism for determining  
646 chain length. *Mol. Microbiol.* **7**:725-734.
- 647 25. **Carter, J. A., J. C. Jimenez, M. Zaldivar, S. A. Alvarez, C. L. Marolda, M. A.**  
648 **Valvano, and I. Contreras.** 2009. The cellular level of O-antigen polymerase Wzy  
649 determines chain length regulation by WzzB and Wzz<sub>pHS-2</sub> in *Shigella flexneri* 2a.  
650 *Microbiology* **155**:3260-3269.
- 651 26. **Woodward, R., W. Yi, L. Li, G. Zhao, H. Eguchi, P. R. Sridhar, H. Guo, J. K.**  
652 **Song, E. Motari, L. Cai, P. Kelleher, X. Liu, W. Han, W. Zhang, Y. Ding, M. Li,**  
653 **and P. G. Wang.** 2010. *In vitro* bacterial polysaccharide biosynthesis: defining the  
654 functions of Wzy and Wzz. *Nat. Chem. Biol.* **6**:418-423.
- 655 27. **Tocilj, A., C. Munger, A. Proteau, R. Morona, L. Purins, E. Ajamian, J. Wagner,**  
656 **M. Papadopoulos, L. Van Den Bosch, J. L. Rubinstein, J. Fethiere, A. Matte,**



- 657       **and M. Cygler.** 2008. Bacterial polysaccharide co-polymerases share a common  
658       framework for control of polymer length. *Nat. Struct. Mol. Biol.* **15**:130-138.
- 659   28.   **Waldo, G. S., B. M. Standish, J. Berendzen, and T. C. Terwilliger.** 1999. Rapid  
660       protein-folding assay using green fluorescent protein. *Nat. Biotechnol.* **17**:691-695.
- 661   29.   **Drew, D., M. Lerch, E. Kunji, D. J. Slotboom, and J. W. de Gier.** 2006.  
662       Optimization of membrane protein overexpression and purification using GFP  
663       fusions. *Nat Methods* **3**:303-313.
- 664   30.   **Murray, G. L., S. R. Attridge, and R. Morona.** 2003. Regulation of *Salmonella*  
665       *typhimurium* lipopolysaccharide O antigen chain length is required for virulence;  
666       identification of FepE as a second Wzz. *Mol. Microbiol.* **47**:1395-1406.
- 667   31.   **Tsai, C. M., and C. E. Frasch.** 1982. A sensitive silver stain for detecting  
668       lipopolysaccharides in polyacrylamide gels. *Anal. Biochem.* **119**:115-119.
- 669   32.   **Purins, L., L. Van Den Bosch, V. Richardson, and R. Morona.** 2008. Coiled-coil  
670       regions play a role in the function of the *Shigella flexneri* O-antigen chain length  
671       regulator Wzz<sub>pHS2</sub>. *Microbiology* **154**:1104-1116.
- 672   33.   **Mavris, M., P. A. Manning, and R. Morona.** 1997. Mechanism of bacteriophage  
673       SfII-mediated serotype conversion in *Shigella flexneri*. *Mol. Microbiol.* **26**:939-950.
- 674   34.   **McKinney, J., C. Guerrier-Takada, J. Galan, and S. Altman.** 2002. Tightly  
675       regulated gene expression system in *Salmonella enterica* serovar Typhimurium. *J.*  
676       *Bacteriol.* **184**:6056-6059.
- 677   35.   **Kim, T. H., S. Sebastian, J. T. Pinkham, R. A. Ross, L. T. Blalock, and D. L.**  
678       **Kasper.** 2010. Characterization of the O-antigen polymerase (Wzy) of *Francisella*  
679       *tularensis*. *J. Biol. Chem.* **285**:27839-27849.

- 680 36. **Knirel, Y. A., O. V. Bystrova, N. A. Kocharova, U. Zahringer, and G. B. Pier.**  
681 2006. Conserved and variable structural features in the lipopolysaccharide of  
682 *Pseudomonas aeruginosa*. J. Endotoxin Res. **12**:324-336.
- 683 37. **Reddy, A., J. Cho, S. Ling, V. Reddy, M. Shlykov, and M. H. Saier.** 2014.  
684 Reliability of nine programs of topological predictions and their application to integral  
685 membrane channel and carrier proteins. Journal of molecular microbiology and  
686 biotechnology **24**:161-190.
- 687 38. **Kenyon, J. J., and P. R. Reeves.** 2013. The Wzy O-antigen polymerase of *Yersinia*  
688 *pseudotuberculosis* O:2a has a dependence on the Wzz chain-length determinant for  
689 efficient polymerization. FEMS Microbiol. Lett. **349**:163-170.
- 690 39. **Schwartz, M.** 1976. The adsorption of coliphage lambda to its host: effect of  
691 variations in the surface density of receptor and in phage-receptor affinity. J. Mol.  
692 Biol. **103**:521-536.
- 693 40. **Islam, S. T., S. M. Huszczyński, T. Nugent, A. C. Gold, and J. S. Lam.** 2013.  
694 Conserved-residue mutations in Wzy affect O-antigen polymerization and Wzz-  
695 mediated chain-length regulation in *Pseudomonas aeruginosa* PAO1. Sci. Rep.  
696 **3**:3441.
- 697 41. **Taylor, V. L., M. L. Udaskin, S. T. Islam, and J. S. Lam.** 2013. The D3  
698 bacteriophage alpha-polymerase inhibitor (lap) peptide disrupts O-antigen  
699 biosynthesis through mimicry of the chain length regulator Wzz in *Pseudomonas*  
700 *aeruginosa*. J. Bacteriol. **195**:4735-4741.

701

702

703 **Tables**704 **Table 1.** Bacterial strains and plasmids used in this study

<b>Strains or Plasmids</b>	<b>Characteristics</b>	<b>Reference</b>
<b><i>S. flexneri</i> Strains</b>		
PE638	<i>S. flexneri</i> Y <i>rpoB</i> (Rif <sup>R</sup> )	(14)
RMM109	PE638 $\Delta$ wzy, Rif <sup>R</sup>	(3)
RMA4337	RMM109 $\Delta$ wzz (Rif <sup>R</sup> , Tet <sup>R</sup> )	This study
PNRM6	RMM109 [pAC/pBADT7-1]	This study
PNRM11	PNRM6 [pWaldo-TEV-GFP]	This study
PNRM13	PNRM6 [pRMPN1]	This study
PNRM75	PNRM6 [pRMPN7]	This study
PNRM76	PNRM6 [pRMPN8]	This study
PNRM77	PNRM6 [pRMPN9]	This study
PNRM78	PNRM6 [pRMPN10]	This study
PNRM79	PNRM6 [pRMPN11]	This study
PNRM80	PNRM6 [pRMPN12]	This study
PNRM81	PNRM6 [pRMPN13]	This study
PNRM82	PNRM6 [pRMPN14]	This study
PNRM83	PNRM6 [pRMPN15]	This study
PNRM84	PNRM6 [pRMPN16]	This study
PNRM85	PNRM6 [pRMPN17]	This study
PNRM119	PNRM6 [pRMPN19]	This study
PNRM120	PNRM6 [pRMPN21]	This study
PNRM121	PNRM6 [pRMPN22]	This study
PNRM122	PNRM6 [pRMPN23]	This study
PNRM123	PNRM6 [pRMPN24]	This study
PNRM124	PNRM6 [pRMPN25]	This study
PNRM126	RMA4337 [pAC/pBADT7-1]	This study
PNRM134	PNRM126 [pRMPN1]	This study
PNRM131	PNRM126 [pRMPN7]	This study
PNRM132	PNRM126 [pRMPN15]	This study
PNRM133	PNRM126 [pRMPN16]	This study
PNRM136	PNRM126 [pRMPN8]	This study
PNRM137	PNRM126 [pRMPN10]	This study
PNRM140	PNRM126 [pRMPN13]	This study
PNRM141	PNRM126 [pRMPN14]	This study
PNRM142	PNRM126 [pRMPN9]	This study
PNRM143	PNRM126 [pRMPN11]	This study
PNRM144	PNRM126 [pRMPN19]	This study
PNRM145	PNRM126 [pRMPN24]	This study
PNRM146	PNRM126 [pRMPN25]	This study
PNRM147	PNRM126 [pRMPN23]	This study
PNRM148	PNRM126 [pRMPN21]	This study

Table 1: cont.

Strains or Plasmids	Characteristics	Reference
<b><i>S. flexneri</i> Strains</b>		
PNRM149	PNRM126 [pRMPN22]	This study
PNRM150	PNRM126 [pRMPN12]	This study
PNRM151	PNRM126 [pRMPN17]	This study
<b><i>E. coli</i> strains</b>		
XL10-G	<i>TetrD[mcrA]183 D[mcrCB-hsdSMR-mrr]173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F' proAB lacIqZDM15 Tn10[Tetr] Camr]</i>	Stratagene
Lemo21[DE3]	<i>fhuA2 [lon] ompT gal [λ DE3] [dcm] ΔhsdS/ pLemo[CamR] λ DE3 = λ sBamHlo ΔEcoRI-B int:: [lacI :: PlacUV5 :: T7 gene1] i21 Δnin5</i>	New England Biolabs
PNRM15	Lemo21(DE3) [pRMPN1]	This study
<b>Plasmids</b>		
pRMCD6	Source of <i>wzy<sub>Sf</sub></i> [modified codons at positions 4, 9, and 23].	(18)
pAC/pBADT7-1	Source of T7 RNA polymerase; Cm <sup>R</sup>	(34)
pWaldo-TEV-GFP	Cloning vector with GFP tag; Km <sup>R</sup>	(28)
pRMPN1	pWaldo- <i>wzy<sub>Sf</sub></i> -GFP; Km <sup>R</sup>	This study
pRMPN7	pRMPN1 with G130V point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN8	pRMPN1 with L111I point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN9	pRMPN1 with N86K point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN10	pRMPN1 with L28V point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN11	pRMPN1 with P165S point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN12	pRMPN1 with G82C point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN13	pRMPN1 with N147K point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN14	pRMPN1 with L191F point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN15	pRMPN1 with L214I point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN16	pRMPN1 with P352H point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN17	pRMPN1 with V92M point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN19	pRMPN1 with F52Y point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN21	pRMPN1 with F52C/I242T point mutations	This study

in the *wzy<sub>Sf</sub>* gene**Table 1:** cont.

Strains or Plasmids	Characteristics	Reference
<b>Plasmids</b>		
pRMPN22	pRMPN1 with C60F point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN23	pRMPN1 with Y137H point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN24	pRMPN1 with L49F/T328A point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pRMPN25	pRMPN1 with F54C point mutation in the <i>wzy<sub>Sf</sub></i> gene	This study
pCACTUS	Suicide vector containing <i>sacB</i> , Cm <sup>R</sup> , and <i>Ori<sub>ts</sub></i>	(14)
pRMA577	Suicide vector containing <i>SphI-SphI</i> fragment with the <i>rol</i> gene	(14)
pCACTUS- <i>wzz<sub>Sf</sub></i> :Tc <sup>R</sup>	Suicide mutagenesis construct to construct the strain RMA4337	This study

705

706 \* Km<sup>R</sup>, Kanamycin-resistant; Cm<sup>R</sup>, Chloramphenicol-resistant; Tc<sup>R</sup>, Tetracycline-resistant.

707

708

709

710

711

712

713

714


715

716 **Table 2.** ColE2 sensitivity, Sf6c sensitivity, and Wzy<sub>Sf</sub>-GFP expression of the controls and different classes of mutants.

Strain	Relevant details			ColE2 sensitivity*		Sf6c sensitivity*		Relative Wzy <sub>Sf</sub> -GFP	
				( $\Delta wzy$ background)	( $\Delta wzy/\Delta wzz$ background)	( $\Delta wzy$ background)	( $\Delta wzy/\Delta wzz$ background)	( $\Delta wzy$ background)	( $\Delta wzy/\Delta wzz$ background)
RMM109	wzy <sub>Sf</sub> mutants			1/256	-	R	-	-	-
PE638	Wild type			R	-	10 <sup>-6</sup>	-	-	-
PNRM13	Positive control			1/2	-	10 <sup>-5</sup>	-	100%	-
PNRM6	Negative control			1/256	-	R	-	-	-
PNRM11	Negative control			1/256	-	R	-	-	-
RMA4337	wzy <sub>Sf</sub> and wzy <sub>Sf</sub> mutant			-	1/256	-	R	-	-
PNRM126	Negative control			-	1/256	-	R	-	-
PNRM134	Positive control			-	R	-	10 <sup>-6</sup>	-	17%
Mutant	Mutant class	Mutant class	Topology map location <sup>#</sup>	ColE2 sensitivity*		Sf6c sensitivity*		Relative Wzy <sub>Sf</sub> -GFP	
				( $\Delta wzy$ background)	( $\Delta wzy/\Delta wzz$ background)	( $\Delta wzy$ background)	( $\Delta wzy/\Delta wzz$ background)	( $\Delta wzy$ background)	( $\Delta wzy/\Delta wzz$ background)
P352H	Class A	Class B	PL6	1/64	1/128	R	R	36%	38%
V92M	Class A	Class E	PL2	1/32	1/64	R	R	84%	76%
Y137H	Class A	Class E	TM5	1/32	1/64	R	R	87%	97%
L214I	Class B	Class C	TM8	1/128	1/128	R	R	1.4%	0.03%
G130V	Class C	Class F	TM5	1/512	1/128	R	R	1.60%	28.50%
N147K	Class D	Class E	PL3	R	1/16	10 <sup>-6</sup>	R	21%	52%
P165S	Class D	Class E	PL3	1/4	1/64	10 <sup>-5</sup>	N	7%	125%
L191F	Class D	Class E	TM7	R	1/16	10 <sup>-6</sup>	N	162%	64%
C60F	Class D	Class E	TM1	R	1/64	10 <sup>-6</sup>	N	30%	66%
L49F/T328A	Class D	Class E	TM2/CL5	R	1/64	10 <sup>-6</sup>	R	65%	68%
L28V	Class D	Class E	PL1	R	1/8	10 <sup>-6</sup>	N	55%	80%
N86K	Class D	Class E	PL2	R	1/64	10 <sup>-6</sup>	R	84%	82%
F54C	Class D	Class E	CL1	R	1/64	10 <sup>-6</sup>	R	42%	71%
F52Y	Class D	Class E	TM2	R	1/64	10 <sup>-6</sup>	R	47%	63%
L111I	Class D	Class E	TM4	R	1/8	10 <sup>-6</sup>	N	41%	51%
G82C	Class D	Class E	PL2	R	1/64	10 <sup>-6</sup>	R	40%	47%
F52C/I242T	Class D	Class E	TM2/TM9	R	1/64	10 <sup>-6</sup>	N	82%	81%

717

718 \*R- Resistant, N- plaques detected with undiluted Sf6c stock; # PL - Periplasmic loop, TM - Trans-membrane region, CL – Cytoplasmic loop (See Fig. 2).

719 **Figures**

720

721 **Fig. 1. Complementation of *wzy<sub>Sr</sub>* deficiency by *Wzy<sub>Sr</sub>*-GFP**

722 LPS samples (equivalent to  $1 \times 10^9$  bacterial cells) were prepared from the strains indicated  
 723 in the figure by proteinase K treatment, electrophoresed on a SDS-15% (w/v) PAGE gel,  
 724 and silver stained (See Materials and Methods). Strains in each lane are as follows: 1.

725 RMM109, 2. PE638, 3. PNRM6 (RMM109 [pAC/pBADT7-1]), 4. PNRM6 [pWaldo-TEV-  
726 GFP], 5. PNRM13 (PNRM6 [pRMPN1]). Positions of S-LPS, SR-LPS, and R-LPS are  
727 indicated. The numbers on the RHS indicate the Oag RU.

728

729

730


731

732

733

734






736 **Fig. 2. Location of the mutations on the topology map of  $Wzy_{Sf}$ .**

737 Mutational alterations were indicated by arrows on the  $Wzy_{Sf}$  topology map (adapted from  
 738 Daniels et al. 1998). The position of the periplasmic loops (PL) 1-5, transmembrane regions  
 739 (TM) 1-12, cytoplasmic loops (CL) 1-5, and inner membrane (IM) are indicated. Mutations  
 740 (shaded circles) were located in the PL – 1, 2, 3, 6; TM – 2, 4, 5, 7, 8, 9; and CL – 1, 5.

741

742

743



744

745 **Fig. 3. LPS phenotype conferred by different  $Wzy_{Sf}$  mutants expressed in PNRM6**  
 746 **( $\Delta wzy_{Sf}$ , [pAC/pBADT7-1]).**

747 Plasmid encoded mutated  $Wzy_{Sf}$  proteins were expressed in PNRM6. Strains were grown  
 748 and induced with arabinose as described in the Materials and Methods. LPS samples were  
 749 prepared, electrophoresed on a SDS-15% (w/v) PAGE gel, and silver stained (See

750 Materials and Methods). Strains were divided into various mutant Classes (A, B, C, and D)  
751 based on their LPS phenotype.

752 Lane 1, the positive control strain PNRM13 (PNRM6 [pRMPN1]). Lanes 2-18 are the  $\Delta wzy$   
753 strain (PNRM6) with plasmids encoding mutated  $Wzy_{sf}$  protein. The  $Wzy_{sf}$  mutants in each  
754 lane are: 2. P352H (Class A), 3.V92M (Class A), 4. Y137H (Class A), 5. L214I (Class B), 6.  
755 G130V (Class C), 7. N147K (Class D), 8. P165S (Class D), 9. L191F (Class D), 10. C60F  
756 (Class D). Position of R-LPS is indicated and the numbers on the LHS indicate the Oag RU.


757

758

759

760

761



762

763 **Fig. 4. Comparison of the LPS phenotype conferred by the  $Wzy_{sf}$  mutants expressed**  
764 **in the  $\Delta wzy$  and  $\Delta wzy \Delta wzz$  backgrounds.**

765 Plasmids encoding mutated  $Wzy_{sf}$  proteins were expressed in PNRM126 (RMA4337  
766 [pAC/pBADT7-1]) and PNRM6 (RMM109 [pAC/pBADT7-1]). Strains were grown and

767 induced as described in the Materials and Methods. LPS samples were electrophoresed on  
768 a SDS-15% (w/v) PAGE gel and silver stained (See Materials and Methods).

769 Lanes 1-3 are: 1. PNRM13, and 2. PNRM126, and 3. PNRM134 (PNRM126 [pRMPN1]).  
770 Lanes 4-36 are the  $\Delta wzy$  (PNRM6) or  $\Delta wzy \Delta wzz$  (PNRM126) strains with plasmids  
771 encoding mutated  $Wzy_{SF}$  protein. The  $Wzy_{SF}$  mutants in each lane are as follows: 4. P352H  
772 ( $\Delta wzy$ ), 5. P352H ( $\Delta wzy \Delta wzz$ ), 6. V92M ( $\Delta wzy$ ), 7. V92M ( $\Delta wzy \Delta wzz$ ), 8. Y137H ( $\Delta wzy$ ),  
773 9. Y137H ( $\Delta wzy \Delta wzz$ ), 10. L214I ( $\Delta wzy$ ), 11. L214I ( $\Delta wzy \Delta wzz$ ), 12. G130V ( $\Delta wzy$ ), 13.  
774 G130V ( $\Delta wzy \Delta wzz$ ), 14. N147K ( $\Delta wzy$ ), 15. N147K ( $\Delta wzy \Delta wzz$ ), 16. P165S ( $\Delta wzy$ ), 17.  
775 P165S ( $\Delta wzy \Delta wzz$ ), 18. L191F ( $\Delta wzy$ ), 19. L191F ( $\Delta wzy \Delta wzz$ ), 20. C60F ( $\Delta wzy$ ), 21.  
776 C60F ( $\Delta wzy \Delta wzz$ ).

777

778

779


780

781

782

783

784



785

786 **Fig. 5. Protein expression level of the mutated  $Wzy_{Sf}$ -GFP compared to the positive**  
 787 **control.**

788 The strains were grown in LB and induced as described in the Materials and Methods. In-  
 789 gel fluorescence samples were prepared from the mutants in the  $\Delta wzy$  and  $\Delta wzy \Delta wzz$   
 790 backgrounds, electrophoresed on SDS 15% (w/v) PAGE gel (See Materials and Methods).

791 **A.** Strains in lanes 1-2 are as follows: 1. PNRM13 (PNRM6 [pRMPN1]), 2. PNRM134  
 792 (PNRM126 [pRMPN1]). Lanes 3-20 are the  $\Delta wzy$  or  $\Delta wzy \Delta wzz$  strains expressing mutated  
 793  $Wzy_{Sf}$ -GFP. The  $Wzy_{Sf}$  mutants in each lane are as follows: 3. P352H ( $\Delta wzy$ ), 4. P352H  
 794 ( $\Delta wzy \Delta wzz$ ), 5. V92M ( $\Delta wzy$ ), 6. V92M ( $\Delta wzy \Delta wzz$ ), 7. Y137H ( $\Delta wzy$ ), 8. Y137H ( $\Delta wzy$   
 795  $\Delta wzz$ ), 9. L214I ( $\Delta wzy$ ), 10. L214I ( $\Delta wzy \Delta wzz$ ), 11. G130V ( $\Delta wzy$ ), 12. G130V ( $\Delta wzy$   
 796  $\Delta wzz$ ).

797 **B.** Strains in lanes 1-2 are as follows: 1. PNRM13, 2. PNRM134. Lanes 2-28 are the  $\Delta wzy$   
798 or  $\Delta wzy \Delta wzz$  strains expressing mutated  $Wzy_{Sf}$ -GFP. The  $Wzy_{Sf}$  mutants in each lane are  
799 as follows: 3. N147K ( $\Delta wzy$ ), 4. N147K ( $\Delta wzy \Delta wzz$ ), 5. P165S ( $\Delta wzy$ ), 6. P165S ( $\Delta wzy$   
800  $\Delta wzz$ ), 7. L191F ( $\Delta wzy$ ), 8. L191F ( $\Delta wzy \Delta wzz$ ), 9. C60F ( $\Delta wzy$ ), 10. C60F ( $\Delta wzy \Delta wzz$ ),  
801 11. L49F/T328A ( $\Delta wzy$ ), 12. L49F/T328A ( $\Delta wzy/ \Delta wzz$ ), 13. L28V ( $\Delta wzy$ ), 14. L28V ( $\Delta wzy$   
802  $\Delta wzz$ ), 15. N86K ( $\Delta wzy$ ), 16. N86K ( $\Delta wzy \Delta wzz$ ), 17. F54C ( $\Delta wzy$ ), 18. F54C ( $\Delta wzy \Delta wzz$ ),  
803 19. F52Y ( $\Delta wzy$ ), 20. F52Y ( $\Delta wzy \Delta wzz$ ), 21. L111I ( $\Delta wzy$ ), 22. L111I ( $\Delta wzy \Delta wzz$ ), 23.  
804 G82C ( $\Delta wzy$ ), 24. G82C ( $\Delta wzy \Delta wzz$ ), 25. F52C/I242T ( $\Delta wzy$ ), 26. F52C/I242T ( $\Delta wzy$   
805  $\Delta wzz$ ).

806

807

808

809

810

811

812

813

814